Prostate Cancer
ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer.
November 1, 2023
Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer: Three Year Outcomes from a Prospective Trial.
October 31, 2023
Making the Case for Autophagy Inhibition as a Therapeutic Strategy in Combination with Androgen-Targeted Therapies in Prostate Cancer.
October 31, 2023
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.
October 30, 2023
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
October 30, 2023
Deep learning-based ultrasound auto-segmentation of the prostate with brachytherapy implanted needles.
October 30, 2023
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer.
October 30, 2023
Clarity and PSI Kick Off SAR-bisPSMA Phase III
October 27, 2023
Novartis Confirms Unconstrained Supply for Pluvicto® and Continues to Significantly Expand the Number of Treatment Centers
October 27, 2023
Robot-Assisted Surgery and Racial and Ethnic Disparities in Post-Prostatectomy Outcomes Among Prostate Cancer Patients.
October 27, 2023
Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer-Combination Strategies.
October 27, 2023
Pelvic irradiation for node-positive prostate cancer after prostatectomy: Long-term results of the prospective PLATIN-4 and PLATIN-5 trials.
October 27, 2023
The long tail of oncogenic drivers in prostate cancer.
October 27, 2023